Testosterone and cardio-metabolic health – a new emerging concept?
Saturday 23 February 2013 1515-1645
Cardiovascular risk factors in men are characterised by obesity, hypertension, insulin resistance, dyslipidaemia, impaired coagulation profile, and chronic inflammation. Visceral fat plays a key role. Adipose tissue as an active endocrine organ produces substances that suppress testosterone production. Low testosterone, however, leads to further accumulation of fat mass. This situation represents a vicious circle.1
Epidemiological studies show that low testosterone is associated with components of the metabolic syndrome as well as inflammation and cardiovascular disease (CVD) in men with or without type 2 diabetes.2, 3, 4 Low testosterone is also associated with increased mortality in older men, both all-cause and caused by CVD. 5
This symposium will provide an update on the latest findings in effects of long-term testosterone treatment in hypogonadal men on cardiovascular risk factors. In parallel with clinical results, basic research reveals an increasing number of mechanisms that contribute to understanding the clinical observations.
L.AU.WH.11.2012.0322
1. Effects of testosterone treatment on obesity in hypogonadal men – facts and hypotheses
Farid Saad, Berlin, Germany
2. Testosterone, diabetes and inflammation – basic research and clinical experience
Andrea M. Isidori, Rome, Italy
3. Insulin sensitivity, lipid metabolism and atherosclerosis – testosterone between endocrinology, diabetology and cardiology
T. Hugh Jones, Sheffield, UK
4. Long-term experience with testosterone in hypogonadal men – from well-being to prevention and treatment of life-threatening diseases
Michael Zitzmann, Münster, Germany
5. Wang C, Jackson G, Jones TH, et al. Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men with Type 2 Diabetes. Diabetes Care, 2011; 34:1669-1675
_____________________________________________________________________________________________
Lilly Men’s Health Symposium
Sunday 24 February 2013 1830-2030
There are many aspects to treating a male patient’s health and with 86% of middle aged men (40-69yrs) visiting a doctor on average 4 times a year, it is important to be aware of and keep up-to-date with the many conditions and factors that can affect your patient.1
Lilly invites you to join renowned speakers, Professor Christina Wang and Professor Matthias Oelke to explore and discuss comprehensive, cutting-edge scientific information in the areas of Andrology and Urology.
This symposium will focus on medical treatment of erectile dysfunction, Australian advances in testosterone replacement therapy for testosterone deficiency and medical management of lower urinary tract symptoms associated with benign prostatic hyperplasia.
References 1. HIS Report. www.HISreport.com.au
Christina Wang, MD, Professor of Medicine and Assistant Dean in Clinical and Translational Sciences at the David Geffen School of Medicine at UCLA.
Dr. Matthias Oelke is Vice-Chairman, Staff Member, and Associate Professor in the Department of Urology, Hanover Medical School, Germany.